Clinical efficacy of farcosolvin syrup (ambroxol&ndash;theophylline&ndash;guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis | Zendy

Mostafa Yakoot | Zendy

Open Access

Clinical efficacy of farcosolvin syrup (ambroxol–theophylline–guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis

Author(s) -

Mostafa Yakoot

Publication year - 2010

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s10981

Subject(s) - medicine , sputum , exacerbation , chronic bronchitis , theophylline , bronchitis , anesthesia , antispasmodic , expectorant , tuberculosis , pharmacology , pathology

Acute exacerbations of chronic bronchitis (AECB) are defined as recurrent attacks of worsening bronchial inflammation that are marked by an increase in the volume of daily sputum produced, a change in color of the expectorated sputum, and worsening dyspnea. Farcosolvin (Pharco Pharmaceuticals, Alexandria, Egypt) is a mixture of ambroxol (15 mg); theophylline (50 mg); and guaiphenesin (30 mg), per 5 mL syrup.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research